Siemens Healthineers' Q4 Test Looms as Deutsche Bank Keeps Neutral Stance and Pipeline Push Continues
Published on 10/06/2026 at 01:20 | Editorial boerse-global.de
Deutsche Bank Research is steering a cautious course into Siemens Healthineers' fourth-quarter earnings, with analyst Falko Friedrichs reaffirming a "Hold" rating and a EUR 39 price target on Monday. The medical technology group is scheduled to report fiscal 2026 fourth-quarter results on November 5, alongside an analyst conference.
Friedrichs anticipates organic revenue growth of six percent for the quarter, though he is bracing for soft profitability. The pending report should shed light on how heavily margin pressures weighed on operations during the period.
Shares were trading at EUR 37.59 in the current session, down 0.9 percent on the day. The stock has shed 16 percent since the turn of the year, underscoring the market's wary posture ahead of the numbers.
Divergent Views Among Analysts
Not everyone on the sell side shares the cautious tone. Julien Dormois of Jefferies reiterated his "Buy" rating and EUR 50 price target on September 30. According to media reports, however, the firm's market commentary flagged that an expected weakening in the diagnostics segment for fiscal 2026 could weigh on the share price.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Dormois also recently characterized the Accela radiotherapy platform as a significant advance in radiation therapy, maintaining his "Buy" call and EUR 50 target.
Product Rollouts and Partnerships
Beyond the earnings outlook, Siemens Healthineers has been busy expanding its product and collaboration portfolio. The company began worldwide distribution of its Innovance D-Dimer 2.0 test in late September. The diagnostic carries both European CE marking and 510(k) clearance from the U.S. Food and Drug Administration, and is designed to reliably rule out deep vein thrombosis and pulmonary embolism in clinical practice.
On September 21, management struck a cooperation agreement with Novo aimed at improving care for patients with the liver conditions MASLD and MASH. The initiative includes stepped-up disease awareness efforts, earlier medical evaluation, and easier access to non-invasive blood tests.
A strategic alliance with Truvian Health, sealed on Thursday, targets further development of the TruVerus blood testing platform. Under the agreement, Siemens Healthineers will contribute development support, technical resources, manufacturing expertise, and commercial guidance.
Radiotherapy Platform Awaits Regulatory Green Light
Roughly a week ago, at the ASTRO 2026 specialist congress, the company unveiled its Accela radiotherapy platform. Built on NeoArc technology, the system is intended to enable multi-site SBRT treatments within 60 seconds. A full commercial launch remains on hold, however, as the system is not yet available in any market and the required 510(k) clearance is still under review.
Buyback Program Presses Ahead
Meanwhile, the company continues to repurchase its own shares. Between September 28 and October 2, Siemens Healthineers bought back 49,987 shares. Since the program's launch on June 1 through October 4 inclusive, the total stands at 3,424,346 repurchased shares.
Ad
Siemens Healthineers Stock: New Analysis - 6 October
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
